Clinical Trials on Stage IIIB Lung Adenocarcinoma AJCC v7

Total 2032 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing Surgery

Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Breast Carcinoma Metastatic in Lymph Node | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7

United States
Ohio State University Comprehensive Cancer Center

Not yet recruiting

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric... and other conditions

United States
University of Washington
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Completed

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Mesothelin Positive

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7 | Stage III Intrahepatic Cholangiocarcinoma AJCC v7 | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant and Adjuvant Checkpoint Blockade

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Stage IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7 | Stage III Acral... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery

Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Esophageal Adenocarcinoma... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Recurrent Breast Carcinoma | HER2/Neu Positive | Progesterone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Canada, Puerto Rico, Ireland
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Terminated

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Metastatic Malignant Neoplasm in the Brain | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
NRG Oncology
National Cancer Institute (NCI)

Completed

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

Fallopian Tube Carcinoma | Endometrial Serous Adenocarcinoma | Ovarian Carcinoma | Malignant Female Reproductive System Neoplasm | Primary Peritoneal Carcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA... and other conditions

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
University of California, San Francisco
Bristol-Myers Squibb Foundation

Completed

Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Malignant Neoplasm | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal... and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIA Esophageal... and other conditions

United States
Jonsson Comprehensive Cancer Center

Completed

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV... and other conditions

United States
Jonsson Comprehensive Cancer Center
Blue Note Therapeutics

Terminated

Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer (BNT001)

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery

Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant Therapy Stage IIIB Gastroesophageal... and other conditions

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7

United States, Canada, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditions

United States
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer... and other conditions

United States, Canada
M.D. Anderson Cancer Center

Active, not recruiting

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Metastatic Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8

United States
Kibo Nam
National Cancer Institute (NCI)

Recruiting

Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
National Cancer Institute (NCI)

Completed

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
OHSU Knight Cancer Institute
Oregon Health and Science University; Taiho Pharmaceutical Co., Ltd.

Recruiting

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

Stage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Ovarian Carcinoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC... and other conditions

United States
National Cancer Institute (NCI)

Completed

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma

United States

Clinical Trials on Stage IIIB Lung Adenocarcinoma AJCC v7

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations